Skip to content
DAEWOONG THERAPEUTICS

Partnering

Bring your molecule. We bring the delivery.

We partner with pharmaceutical and biotechnology companies of all sizes, offering flexible collaboration models and well-defined execution plans tailored to each partner's needs.

Start a conversation
  • CLOPAM® · Thermicra™
  • Feasibility under MTA
  • Co-development · Licensing

01 — Which platform fits?

Start from your challenge

Potent molecules go through the skin with CLOPAM. High-dose biologics go under it with Thermicra.
  • EPIDERMISDERMISSUBCUTIS

    CLOPAM®

    Dissolving microneedle patch

    Route
    Into the skin · a self-applied patch
    Dose
    Potent molecules, micrograms to milligrams

    If you need…

    Molecules

    • Peptides
    • Hormones
    • Vaccines
    • Small molecules
    • mRNA

    Explore CLOPAM

  • EPIDERMISDERMISSUBCUTIS

    Thermicra™

    Ultra-high concentration formulation for subcutaneous injection

    Route
    Under the skin · one small SC injection
    Dose
    Biologics, hundreds of milligrams

    If you need…

    • High-dose subcutaneous deliveryYour dose is too large for a standard SC injection.
    • IV-to-SC conversionMove an IV biologic out of the infusion chair.
    • SC for ADCs and AOCs Conjugates that conventional processes cannot concentrate.
    • SC without hyaluronidase An SC biosimilar, outside the enzyme's patent families.
    • Simpler preparationA ready-to-inject dose instead of a pharmacy preparation.

    Molecules

    • mAbs
    • ADCs
    • AOCs
    • Bispecifics
    • Proteins

    Explore Thermicra

02 — Collaboration model

Step by step, starting with data

We start small and grow the partnership with the results.

  1. Stage 01

    Feasibility under an MTA

    Validate the platform on your own molecule under a material transfer agreement.

  2. Stage 02

    Research collaboration

    Build on the feasibility data and develop the formulation together.

  3. Stage 03

    Licensing

    License the platform for your program.

  4. Stage 04

    Commercialization

    Take the product to market with our continued technical support.

  • 01

    Start with data

    An MTA-based feasibility evaluation lets you validate the platform on your molecule first.

  • 02

    Expand step by step

    The partnership grows with the study outcomes, at a pace that suits your program.

  • 03

    Flexible terms

    Open to discussion, with flexible terms shaped around your program.

03 — Initial feasibility evaluation

Who does what

A clear split of work, so the first study starts quickly.

Provided by Daewoong Therapeutics

  • Formulation study & process optimization

    • Excipient screening
    • Process optimization for your molecule

  • Sample manufacturing & DP evaluation

    • Lab-scale sample manufacturing
    • Stability study
    • In vivo PK study

  • Optional services

    • Reproducibility test
    • Pilot-scale manufacturing

Partner's part

  • Drug substance / API

    • Supply of the drug substance for the study

  • Analytical methods

    • Transfer of the analytical method(s) for the drug substance

04 — How we work

From first email to agreement

  1. Step 01

    Inquiry

    Tell us about your molecule and goals.

  2. Step 02

    Quick meeting

    A short call on non-confidential information, to see whether there is a fit.

  3. Step 03

    CDA

    We sign a confidentiality agreement before exchanging details.

  4. Step 04

    Feasibility

    Under an MTA, we evaluate your molecule and share the data.

  5. Step 05

    Agreement

    We agree the collaboration model and terms.

Tell us about your molecule.

We'll sign a CDA before any confidential details are shared.
Contact our BD team